<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 S2678 IS: STOP Pain Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2016-03-15</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>114th CONGRESS</congress><session>2d Session</session><legis-num>S. 2678</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20160315">March 15, 2016</action-date><action-desc><sponsor name-id="S353">Mr. Schatz</sponsor> (for himself, <cosponsor name-id="S118">Mr. Hatch</cosponsor>, <cosponsor name-id="S314">Mr. Tester</cosponsor>, <cosponsor name-id="S136">Mr. Cochran</cosponsor>, <cosponsor name-id="S252">Ms. Collins</cosponsor>, and <cosponsor name-id="S354">Ms. Baldwin</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name added-display-style="italic" committee-id="SSHR00" deleted-display-style="strikethrough">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To direct the NIH to intensify and coordinate fundamental, translational, and clinical research
			 with respect to the understanding of pain, the discovery and development
			 of therapies for chronic pain, and the development of alternatives to
			 opioids for effective pain treatments.</official-title></form>
	<legis-body>
 <section id="idB2D2683C9DB143F3A0D0C2BC2AE254AE" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Safe Treatments and Opportunities to Prevent Pain Act</short-title></quote> or the <quote>STOP Pain Act</quote>.</text> </section><section id="id036D1C4757DA44088211010DBDDA5CEE"><enum>2.</enum><header>Enhancing basic and applied research on pain to discover therapies, including alternatives to opioids, for effective pain management</header> <subsection id="id8237126d59be42b3896d071d56d9d23b"><enum>(a)</enum><header>In general</header><text>The Director of the National Institutes of Health (referred to in this section as the <quote>NIH</quote>) may intensify and coordinate fundamental, translational, and clinical research of the NIH with respect to—</text>
 <paragraph id="id3AD9804C70BE4686996CB796DE955A65"><enum>(1)</enum><text>the understanding of pain;</text> </paragraph><paragraph id="id2BF5D758E8114E5B96DF6565B202B9D2"><enum>(2)</enum><text>the discovery and development of therapies for chronic pain; and</text>
 </paragraph><paragraph id="id10A9A68333724C2D9A8B07FE76EB24AB"><enum>(3)</enum><text>the development of alternatives to opioids for effective pain treatments.</text> </paragraph></subsection><subsection id="id68e16cd507ca4e72a5061b46a8956832"><enum>(b)</enum><header>Priority and direction</header><text>The prioritization and direction of the federally funded portfolio of pain research studies shall consider recommendations made by the Interagency Pain Research Coordinating Committee in concert with the Pain Management Best Practices Inter-Agency Task Force, and in accordance with the National Pain Strategy, the Federal Pain Research Strategy, and the NIH-Wide Strategic Plan for Fiscal Years 2016–2020, the latter which calls for the relative burdens of individual diseases and medical disorders to be regarded as crucial considerations in balancing the priorities of the Federal research portfolio.</text></subsection></section></legis-body></bill>


